Dupixent(dupilumab)
Dupixent (dupilumab) is an antibody pharmaceutical. Dupilumab was first approved as Dupixent on 2017-03-28. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat asthma, atopic dermatitis, esophageal diseases, prurigo, and sinusitis. The pharmaceutical is active against interleukin-4 receptor subunit alpha. In addition, it is known to target Interleukin 4 receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Dupixent
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Dupilumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Dupixent | dupilumab | Regeneron Pharmaceuticals | N-761055 RX | 2017-03-28 | 5 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dupixent | Biologic Licensing Application | 2021-01-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| atopic dermatitis | EFO_0000274 | D003876 | L20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
dupilumab, Dupixent, Regeneron Pharmaceuticals, Inc. | |||
| 2029-05-20 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
164 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 4 | 10 | 16 | 20 | 10 | 59 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | 6 | 8 | 9 | 7 | 31 |
| Nasal polyps | D009298 | HP_0100582 | J33 | — | 2 | 2 | 4 | 5 | 13 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | 1 | 4 | — | 6 |
| Eosinophilic esophagitis | D057765 | EFO_0004232 | K20.0 | — | 1 | 2 | 1 | 1 | 5 |
| Allergic contact dermatitis | D017449 | L23 | — | 1 | 1 | 1 | — | 2 | |
| Keloid | D007627 | EFO_0004212 | L91.0 | — | 1 | — | 1 | — | 2 |
| Lamellar ichthyosis | D017490 | Q80 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bullous pemphigoid | D010391 | EFO_0007187 | L12 | — | 1 | 1 | — | 2 | 3 |
| Chronic urticaria | D000080223 | L50.8 | — | 1 | 2 | — | — | 3 | |
| Dermatitis | D003872 | HP_0011123 | L30.9 | 1 | — | 2 | — | — | 3 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 2 | — | — | 2 |
| Pruritus | D011537 | HP_0000989 | L29 | — | 1 | 1 | — | — | 2 |
| Neurodermatitis | D009450 | L28.0 | — | — | 2 | — | — | 2 | |
| Immune system diseases | D007154 | D89.9 | — | — | 2 | — | — | 2 | |
| Skin diseases | D012871 | L00-L99 | 1 | — | 1 | — | — | 2 | |
| Eczematous skin diseases | D017443 | — | — | 2 | — | — | 2 | ||
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | 1 | — | — | 2 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peanut hypersensitivity | D021183 | EFO_0007425 | — | 3 | — | — | — | 3 | |
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | 2 | — | — | — | 2 |
| Respiration disorders | D012120 | J00-J99 | — | 1 | — | — | — | 1 | |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | 1 | — | — | — | 1 |
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | 1 | — | — | — | 1 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 1 | — | — | — | 1 |
| Eosinophilia | D004802 | HP_0001880 | D72.1 | — | 1 | — | — | — | 1 |
| Keratoconjunctivitis | D007637 | H16.2 | — | 1 | — | — | — | 1 | |
| Localized scleroderma | D012594 | L94.0 | — | 1 | — | — | — | 1 | |
| Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 4 | — | — | — | — | 4 | ||
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | — | 1 | 1 |
| Conjunctivitis | D003231 | H10 | — | — | — | — | 1 | 1 | |
| Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DUPILUMAB |
| INN | dupilumab |
| Description | Dupilumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >6WG8:A|Dupilumab Fab heavy chain
EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLY
LQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGHHHHHH
>6WG8:B|Dupilumab Fab light chain
DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKI
SRVEAEDVGFYYCMQALQTPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ
SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTQGTTSVTKSFNRGEC |
Identifiers
| PDB | 6WG8, 6WGB, 6WGJ, 6WGK, 6WGL |
| CAS-ID | 1190264-60-8 |
| RxCUI | 1876376 |
| ChEMBL ID | CHEMBL2108675 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12159 |
| UNII ID | 420K487FSG (ChemIDplus, GSRS) |
Target
Agency Approved
IL4R
IL4R
Organism
Homo sapiens
Gene name
IL4R
Gene synonyms
IL4RA
NCBI Gene ID
Protein name
interleukin-4 receptor subunit alpha
Protein synonyms
CD124, IL-4 receptor subunit alpha, interleukin 13 receptor, interleukin-4 receptor alpha chain
Uniprot ID
Mouse ortholog
Il4ra (16190)
interleukin-4 receptor subunit alpha (Q8CBW5)
Alternate
IL4R
IL4R
Organism
Homo sapiens
Gene name
IL4R
Gene synonyms
NCBI Gene ID
—
Protein name
Interleukin 4 receptor
Protein synonyms
Uniprot ID
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
Dupixent - Sanofi
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Dupixent - Regeneron Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,245 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
44,077 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more